Kamada Shuts Down Phase 3 Study For Genetic Condition, Reiterates Outlook
Kamada discontinues Phase 3 trial for inhaled AAT due to limited efficacy. Shares down 5.51% following the trial discontinuation announcement. CEO emphasizes strong growth prospects despite trial outcome. Full-year 2025 revenue guidance remains between $178M to $182M. Kamada plans double-digit growth through commercial portfolio expansion.
View signal analysis